3 results
To investigate the efficacy of repeated daily doses of nebulised RPL554 (0.018 mg/kg) by assessing the effect on FEV1 at day 1, 3 and 6 after daily inhaled doses of nebulised RPL554 0.018 mg/kg (6X) in 16 allergic asthmatics.
Objective: To demonstrate the non-inferiority of ertugliflozin compared with anon-ertugliflozin comparator group on the time to first occurrence of any of thecomponents of the composite endpoint of cardiovascular death, non-fatal…
Primary objectives1A. To evaluate the effect of maximal LDL-C reduction by Evolocumab on top of high intensity lipid-lowering therapy , initiated immediately after invasive ACS treatment on functional impairment of non-infarct related artery (non-…